earnings
confidence high
sentiment positive
materiality 0.75
Cardiff Oncology reports Q1 cash $46.1M, FDA aligns on Phase 3 design for onvansertib
Cardiff Oncology, Inc.
2026-Q1 EPS reported
-$0.18
revenue$41,000
- Cash and investments $46.1M at Q1 end; net cash used $12.3M, runway into Q1 2027.
- Completed End-of-Phase 2 FDA meeting; selected 30 mg onvansertib + FOLFIRI/bev for Phase 3.
- Phase 2 CRDF-004: 30 mg arm ORR 72.2% vs SoC 43.2%; PFS HR 0.38 vs FOLFIRI/bev.
- Appointed Mani Mohindru as permanent CEO, Josh Muntner as CFO, Ajay Aggarwal as COO.
- Updated onvansertib data to be presented at ASCO 2026 rapid oral presentation.
item 2.02item 9.01